Skip to main content

Table 4 Univariate and multivariate Cox proportional hazards regression models of overall survival in 62 HCC patients

From: Liver-specific lncRNA FAM99A may be a tumor suppressor and promising prognostic biomarker in hepatocellular carcinoma

Clinicopathological features

Univariate analysis

Multivariable analysis

β

HR

95%CI

P

β

HR

95%CI

P

Age (≥ 50 years vs.< 50 years)

0.274

1.315

0.638-2.712

0.458

    

Sex (female vs. male)

0.101

1.107

0.423-2.892

0.836

    

Liver cirrhosis (positive vs. negative)

0.528

1.695

0.726-3.956

0.222

    

Hepatitis B virus infection (positive vs. negative)

-0.327

0.721

0.275-1.890

0.506

    

AFP (> 400 ng/ml vs. ≤ 400 ng/ml)

0.173

1.188

0.580-2.435

0.637

    

Tumor number (multiple vs. single)

0.631

1.880

0.806-4.386

0.144

    

Lymph nodes metastasis (positive vs. negative)

0.938

2.555

0.765-8.539

0.127

    

Tumor size (≥ 7cm vs. < 7cm)

0.802

2.229

1.059-4.691

0.035

0.635

1.887

0.768-4.634

0.166

BCLC stage (C vs. B vs. A)

0.440

1.553

1.053-2.292

0.027

0.036

1.037

0.652-1.648

0.878

Child-Pugh classification grade (B vs. A)

1.319

3.738

1.286-10.865

0.015

0.432

1.540

0.428-5.545

0.509

Microvascular invasion (positive vs. negative)

1.181

3.256

1.446-7.332

0.004

0.979

2.661

1.102-6.427

0.030

Edmondson-Steiner grade (III-IV vs. I-II)

0.708

2.030

0.948-4.346

0.068

0.933

2.543

1.069-6.048

0.035

FAM99A expression (high vs. low)

-0.960

0.383

0.179-0.820

0.013

-0.855

0.425

0.189-0.958

0.039

  1. Statistically significant P values are in bold (P < 0.10)
  2. HCC hepatocellular carcinoma; AFP alpha-fetoprotein; BCLC Barcelona Clinic Liver Cancer; HR hazard ratio; CI confidence interval